| |
Total
|
Group
|
p Value
|
|---|
|
A
|
A + 25 W
|
A + 35 W
|
A + 45 W
|
|---|
|
n = 109
|
n = 23
|
n = 34
|
n = 28
|
n = 24
|
|---|
|
Age, years
|
70 ± 10
|
75 ± 9
|
68 ± 10
|
69 ± 10
|
71 ± 8
|
0.056
|
|
Male, %
|
41
|
48
|
32
|
39
|
50
|
0.508
|
|
Previous MI, %
|
4
|
13
|
3
|
0
|
0
|
0.051
|
|
Previous PCI, %
|
16
|
39
|
12
|
11
|
4
|
0.051
|
|
Cerebrovascular disease, %
|
17
|
31
|
7
|
14
|
25
|
0.071
|
|
Peripheral artery disease, %
|
8
|
22
|
3
|
7
|
4
|
0.061
|
|
Hypertension, %
|
62
|
73
|
65
|
54
|
58
|
0.479
|
|
Dyslipidemia, %
|
57
|
68
|
62
|
46
|
54
|
0.051
|
|
Diabetes mellitus, %
|
41
|
46
|
38
|
46
|
33
|
0.782
|
|
Atrial fibrillation, %
|
5
|
9
|
3
|
7
|
0
|
0.445
|
|
Current Smoking, %
|
15
|
23
|
15
|
11
|
13
|
0.715
|
|
Laboratory data
|
|
Hb, g/dL
|
13.6 ± 1.7
|
12.7 ± 1.7
|
13.6 ± 1.4
|
14.1 ± 1.9
|
13.9 ± 1.8
|
0.051
|
|
HbA1c, %
|
7.8 ± 2.6
|
6.7 ± 1.2
|
8.2 ± 2.7
|
8.4 ± 3.2
|
7.4 ± 2.5
|
0.216
|
|
UA, mg/dL
|
5.4 ± 1.5
|
5.1 ± 0.8
|
5.2 ± 1.5
|
5.8 ± 1.8
|
5.6 ± 1.8
|
0.415
|
|
LDL-C, mg/dL
|
122 ± 35
|
108 ± 29
|
122 ± 30
|
139 ± 35
|
113 ± 41
|
0.036
|
|
HDL-C, mg/dL
|
54 ± 26
|
53 ± 15
|
61 ± 41
|
51 ± 10
|
48 ± 20
|
0.493
|
|
Creatinine, mg/dL
|
0.92 ± 0.64
|
1.23 ± 1.15
|
0.77 ± 0.21
|
0.81 ± 0.37
|
0.97 ± 0.45
|
0.054
|
|
BNP, pg/mL
|
49 (22, 78)
|
58 (22, 208)
|
48 (23, 68)
|
59 (15, 65)
|
40 (11, 63)
|
0.067
|
|
Medications
|
|
ADA, %
|
22
|
14
|
27
|
29
|
17
|
0.167
|
|
ATA, %
|
22
|
36
|
27
|
11
|
17
|
0.192
|
|
β blocker, %
|
14
|
14
|
18
|
18
|
4
|
0.440
|
|
CCB, %
|
46
|
55
|
47
|
46
|
38
|
0.634
|
|
Diuretics, %
|
8
|
14
|
6
|
11
|
4
|
0.374
|
|
Nitrates, %
|
7
|
14
|
9
|
7
|
0
|
0.636
|
|
RAS-I, %
|
37
|
36
|
27
|
36
|
54
|
0.075
|
|
Statin, %
|
41
|
57
|
44
|
21
|
42
|
0.462
|
- Data are mean ± SD or percentage except for BNP level (median, 25–75%)
- MI myocardial infarction, PCI percutaneous coronary intervention, Hb hemoglobin, UA uric acid, LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol, BNP brain natriuretic peptide, ADA antidiabetic agents, ATA antithrombotic agents, CCB calcium-channel blocker, RAS-I renin-angiotensin system inhibitor
